DBV Technologies Announces Q3 2025 Financial Results

DBV Technologies, a biopharmaceutical company specializing in the treatment of food allergies, has released its financial results for the third quarter of 2025. The company reported cash of $69.8 million, sufficient to fund its operations through the third quarter of 2026. Research tax credits increased, thanks to increased qualifying activities, reaching $5 million for the first nine months.

Operating expenses increased to $107 million, primarily due to the COMFORT Toddlers safety study. Net loss for the same period was $102.1 million, or $0.82 per share.

DBV raised $306.9 million to develop the Viaskin® Peanut patch. Despite improved cash flow, going concern is uncertain. The company is exploring additional financing and remains attentive to market conditions and investor interest.